Breast cancers presenting luminal B subtype features show higher discordant human epidermal growth factor receptor 2 results between immunohistochemistry and fluorescence in situ hybridization

Achieving 95% Cross-Methodological Concordance in HER2 Testing

(2010) Erin E. Grimm et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study

(2010) Shaheenah Dawood et al.   BREAST CANCER RESEARCH AND TREATMENT

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer

(2009) Sejal S. Shah et al.   HUMAN PATHOLOGY

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations

(2009) Guido Sauter et al.   JOURNAL OF CLINICAL ONCOLOGY

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

(2009) Maggie C. U. Cheang et al.   JNCI-Journal of the National Cancer Institute

HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry

(2009) Anikó Kovács et al.   PATHOLOGY RESEARCH AND PRACTICE

Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients

(2008) R. Stuart-Harris et al.   BREAST

The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2

(2008) Aleix Prat et al.   Nature clinical practice. Oncology

Systematic Review of HER2 Breast Cancer Testing

(2008) Marta Cuadros et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY